Quick Answer
Zentalis Pharmaceuticals, Inc. reported Cash and Equivalents of $35.99 million for fiscal year 2025.
Zentalis Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $35.99M | +6.2% |
| 2024 | $33.90M | +20.9% |
| 2023 | $28.04M | -34.9% |
| 2022 | $43.07M | -27.9% |
| 2021 | $59.71M | +8.7% |
| 2020 | $54.95M | -18.3% |
| 2019 | $67.25M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $39.07M | -5.4% | +3.9% |
| June 30, 2025 | $37.60M | +1.7% | -10.3% |
| March 31, 2025 | $41.93M | +11.5% | +23.7% |
| December 31, 2024 | $33.90M | +20.9% | -18.0% |
| September 30, 2024 | $41.32M | -62.7% | +11.7% |
| June 30, 2024 | $36.98M | -86.1% | -1.7% |
| March 31, 2024 | $37.62M | +3.7% | +34.2% |
| December 31, 2023 | $28.04M | -34.9% | -74.7% |
- Zentalis Pharmaceuticals, Inc. showed an increase of +6.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Zentalis Pharmaceuticals, Inc.’s cash and equivalents has declined by 46.5% (from $67.25 million to $35.99 million).
- The most recent figure is from Zentalis Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: